Terumo Cardiovascular Group

e-mail usprint


Systemic inflammatory response syndrome (SIRS) results in generalized edema and dysfunction of critical organ systems. It can be alleviated by reducing harmful exposure of blood and tissue to air and/or non-biological surfaces in the extracorporeal circuit.

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

ABSTRACT: Improving Cardiac Surgery Outcomes: Leukocyte Filtration
Amit Patel, MD, presents his outcome data on 2,000 patients undergoing cardiac surgery with leukocyte filtration at the July 2004 Hammersmith Meeting.

ABSTRACT: Investigation of Blood Compatibility of PMEA-Coated Extracorporeal Circuits. Journal of Bioactive and Compatible Polymers, Vol 17, Sept 2002. Kocakulak M, et al.
In a study comparing PMEA-coated and uncoated oxygenators, the authors found greater retention of clotting factors and platelets and less post-op hemorrhaging when using PMEA-coated oxygenators.

ABSTRACT: Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic CPB. Cardiovascular and Hematological Agents. 2004; Vol. 2:No 4. Gunaydin S, et al.
The authors compare surface coatings, including Xcoating, in 155 CPB cases for chemical composition, biomaterial evaluation and clinical efficacy.

ABSTRACT: Biocompatibility of Poly (2-methoxyethylacrylate) Coating for Cardiopulmonary Bypass. Annals Thoracic Cardiovascular Surgery, 2003, Volume 9, No 1. Noguchi, et al.
The authors compare the biocompatibility of PMEA-coated and heparin-coated circuits by measuring several inflammatory markers. Results indicate PMEA-coated circuits are as biocompatible as heparin coated circuits.

ABSTRACT: Xcoating: A New Biopassive Polymer Coating. Canadian Perfusion Canadienne, Volume 11, No 2, June 2001. Schiel, et al.
This paper explains the mechanism and benefits of Xcoating.

ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.

ABSTRACT: Beneficial Effects of Modern Perfusion Concepts in Aortic Valve and Aortic Root Surgery. Perfusion 2009;24: 37-44, Kutschka, et al.
In this 170-patient study, the use of the ROCSafe™ Hybrid Perfusion System was found to reduce side effects of standard extracorporeal circulation.

ABSTRACT: Intraoperative Treatment Strategy to Reduce the Incidence of Post-Cardiopulmonary Bypass Atrial Fibrillation. Perfusion 2002; V 17. O-Yurvati A.
In this study, the authors demonstrate a 72% reduction in the incidence of post-op atrial fibrillation in patients who receive leukocyte filtration and aprotinin, resulting in $8,725 savings per patient.

ABSTRACT: Clinical Evaluation of a Leuko-Depleting Blood Cardioplegia Filter (BC1B) for Elective Open-Heart Surgery. Perfusion 1998; 13: 205-210. Suzuki, et al.
In this study of 40 CABG patients, the authors demonstrate the ability of the Pall BC1 filter to remove inflammatory mediators CPK-MB and troponin.

ABSTRACT: The Role of Leukocyte Depleting Filters in Heart Transplantation: Early Outcomes in Prospective, Randomized Clinical Trial. European Journal of Cardiothoracic Surgery. October 2006; 30: 621-627. Dvorak, et al.
In this study of 40 patients, the authors find leukocyte filtration reduces markers of reperfusion injury, time on ventilation and time in the ICU, and improves graft functionality.

ANIMATION: Prescriptive Oxygenation 3-D Animation
This animation illustrates how Terumo's unique oxygenators, packaging solutions and brackets make implementing Prescriptive Oxygenation quick and convenient.